Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2009

View Archived Issues

Interim clinical data reported for SCH-900518 combination regimens

Pfizer submits Lipitor data to EMEA

TB-403 shown to be safe in healthy males and cancer patients in phase I trials

Cel-Sci initiates first clinical study of LEAPS-H1N1 therapy in H1N1

Mitsubishi Tanabe reports results from quarter ended September 30, 2009

Schering-Plough reports results from third quarter of 2009

VALIANT study results suggest increased HR is predictive of worse outcome in post-MI

Insight into the mechanism of action of ATI-5261, a novel synthetic peptide

Chymase inhibitor improves left ventricular function after mitral regurgitation

CytRx to initiate phase II clinical trial of INNO-206 in advanced gastric cancer

Clinical Data starts phase III Stedivaze trial for cardiac stress testing

Phase I data analysis triggers clinical advance of Alzheimer's disease vaccine

Altair Therapeutics initiates multicenter phase IIa trial of AIR-645 in asthma

First patient cohort enrolled in Dynavax Technologies' phase Ib trial of DV-601 in hepatitis B

Insulin secretion stimulators described by Merck KGaA for the treatment of hyperglycemia

BMS claims four series of novel NS5B inhibitors for treatment of HCV infection

Astellas and XenoPort submit NDA in Japan for ASP-8825 for RLS

Novel antimitotic agents claimed by Korean scientists for the treatment of cancer

AstraZeneca claims chemokine CX3CR1 receptor antagonists

Epiphany Biosciences reports results from phase IIb trial of valomaciclovir in shingles

Otsuka withdraws its application to EMEA for extended indication of Abilify

Synairgen completes phase I safety trial of inhaled IFN-beta in asthma

Jennerex and Lee's enter into license agreement for cancer drug JX-594 in China

FDA reports new safety information concerning drug-drug interactions with clopidogrel

Pfizer and DNDi enter research collaboration for drugs against tropical diseases

Advanced Cell Technology files IND with FDA to initiate phase I/II trial in Stargardt's disease